Skip to content

NORCCAP: Norwegian Colorectal Cancer Prevention Trial

Norwegian Colorectal Cancer Prevention Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00119912
Acronym
NORCCAP
Enrollment
100000
Registered
2005-07-14
Start date
1999-01-01
Completion date
2036-12-01
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenoma, Colorectal Cancer

Keywords

screening, flexible sigmoidoscopy, fecal occult blood, cancer, colon, rectum

Brief summary

The purpose of this study is to see if screening with flexible sigmoidoscopy (a flexible viewing tube) may reduce large bowel cancer and cancer deaths. The researchers also want to see if the addition of screening for occult blood in stools may contribute further to this aim. Additionally, the researchers also want to see to which extent (and in which direction) the study may influence overall endoscopic activity in the general population in the screening area and in areas where controlled screening is not established.

Detailed description

Although flexible sigmoidoscopy (FS) as a screening tool has a much higher test sensitivity than fecal occult blood tests (FOBT) for colorectal cancer and high-risk adenomas, randomised trials with long-term follow-up are missing. The primary aim is to evaluate the effect on CRC mortality and morbidity by screen detection of CRC and removal of precursor lesions (polypectomy of adenomatous polyps) Secondary aims: 1. Evaluation of cost/effectiveness of screening for CRC and significant, benign lesions using flex-sig only compared to flex-sig in combination with faecal tests 2. To evaluate to which extent (and in which direction) the study may influence overall endoscopic activity in the general population in the screening areas and in areas where controlled screening is not established 3. Determine the prevalence of known types familial CRC in a general population and try to define other groups with intermediate increased risk 4. Clarify possible psychosocial effects of endoscopic screening and how it may influence lifestyle and lifestyle related morbidity and overall mortality Population: 21,000 men and women, aged 50-64 years, living in the city of Oslo or the county of Telemark are drawn by randomisation (approx. 1:5) from the population registry and invited to have a flexible sigmoidoscopy examination. The control group constitutes 79,000 individuals. Those invited for flexible sigmoidoscopy are further randomised (1:1) to bring or not to bring 3 successive stool samples for FOBT on attendance for FS. Method: This is a once-only screening concept with bowel cleansing being limited to a 240 ml Sorbitol enema given on attendance. The threshold for work-up colonoscopy is low as a positive screening test is defined as any polyp \>9mm, any histologically verified adenoma irrespective of size and a positive FOBT. The screening phase is limited to the period January 1999- January 2002 and the first follow-up results will not be reported until all entries have passed the 5-year mark (i.e. in early 2007).

Interventions

PROCEDUREA 1 Intervention arm Flex Sig

Screening by flexible sigmoidoscopy

PROCEDUREA 2 Intervention arm Flex Sig + iFOBT

In addition to Flexible Sigmoidoscopy, half of arm A (randomised 1:1) is invited to provide stool samples for FOBT

Sponsors

Norwegian Institute of Public Health
Lead SponsorOTHER_GOV
Norwegian Cancer Society
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to 64 Years
Healthy volunteers
Yes

Inclusion criteria

* Men and women * Living in Oslo or Telemark * Age 50-64 years

Exclusion criteria

* Patients with previous open colorectal surgery (resections, enterostomies) * Individuals in need of long lasting attention and nursing services (somatic or psychosocial reasons, mental retardation) * On-going cytotoxic treatment or radiotherapy for malignant disease * Severe chronic cardiac or lung disease (NYHA III-IV) * Patients with heart valve replacement on life long anticoagulant therapy * A coronary event during the last 3 months if having lead to hospitalisation * Cerebrovascular accident during the last 3 months * Resident abroad

Design outcomes

Primary

MeasureTime frameDescription
1. Evaluate the effect on CRC mortality and morbidity by screen detection of CRC and removal of precursor lesions (polypectomy of adenomatous polyps).First evaluation after 5 years.Evaluations in 2007 (published),2012,2017CRC incidence and mortality is followed

Secondary

MeasureTime frameDescription
1. Determine the prevalence of known types familial CRC in a general population and try to define other groups with intermediate increased risk. Results "in press" 2005.Evaluated in 2005 (published)Determine the prevalence of familial CRC in a general population sample
2. Clarify possible psychosocial effects of endoscopic screening and how it may influence lifestyle and lifestyle related morbidity and overall mortality. Evaluation in 2005.Evaluated in 2005 (published)Determine psychosocial effects of invitation to screening and of screening findings

Countries

Norway

Contacts

STUDY_CHAIRGiske Ursin, M.D.

Norwegian Institute of Public Health

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 14, 2026